

Exhibit 22

*State of California ex. rel. Ven-A-Care of the Florida Keys, Inc. v.
Abbott Laboratories, Inc., et al.*

Exhibit to the Declaration of Nicholas N. Paul in Support of
Plaintiffs' Opposition to Defendants' Joint Motion for Partial Summary Judgment

Minneapolis, MN

Page 1

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

- - - - - x

IN RE: PHARMACEUTICAL) MDL NO. 1456
INDUSTRY AVERAGE WHOLESALE) Master File No. 01-12257-PBS
PRICE LITIGATION) Subcategory Case No. 06-11337
-----)

THIS DOCUMENT RELATES TO:) Hon. Patti B. Saris
State of California, ex rel.)
Ven-A-Care v. Abbott) Tuesday, September 15, 2009
Laboratories, Inc., et al.)

- - - - - x VOLUME I

Videotaped deposition of STEPHEN W.
SCHONDELMEYER, PHARM.D., Ph.D., held at the Grand
Hotel, 615 2nd Avenue South, Minneapolis,
Minnesota, commenced at 9:11 a.m., the
proceedings being recorded stenographically by
Dawn Workman Bounds, Certified Shorthand Reporter
and Notary Public of the State of Minnesota, and
transcribed under her direction.

Minneapolis, MN

Page 206

1 Q. In part, right.

2 And among the published prices, the FUL
3 -- they use are published WACs and published
4 AWP, right?

5 A. Are you talking federal or the
6 California --

7 Q. Federal. The federal.

8 A. I believe the feds use both the WACs
9 and AWP when they exist.

10 Q. So if a FUL is set on a drug for
11 reimbursement in California, no matter how high
12 Mylan or Dey or Sandoz raises its AWP on that
13 drug with the FUL, it is not going to affect how
14 much California reimburses on that transaction,
15 if we assume that each of those defendants report
16 a WAC that's lower than the AWP, correct?

17 A. I would have to think about that and
18 think through the circumstances.

19 It's conceivable if their AWP was lower
20 than what the federal upper limit was, that the
21 AWP could determine the payment, rather than the
22 federal upper limit.